Overexpression of PD-L1 is significantly related to the efficacy of PD-1/PD-L1 inhibitors in many tumor types, such as melanoma (44, 100), NSCLC (100), renal cell carcinoma, ovarian cancer. The gene discussed is CD274; the disease is renal cell carcinoma.